Ranbaxy to sell slimming pills in Canada

New Delhi: Leading pharmaceutical company Ranbaxy Laboratories has got the nod from Canada's Therapeutic Products Directorate (TPD) to manufacture and market Ran-Pravastatin, used to reduce cholesterol.

The approval for the marketing of tablets, in multiple dosages of 10 mg, 20 mg, and 40 mg, would open up Canadian Dollar 72.9 million annual markets for Pravastatin in Canada.

Ranbaxy on Monday informed the Bombay Stock Exchange (BSE) about the approval.

"We are pleased to receive this approval for Ran-Pravastatin to expand the number of product offerings that Ranbaxy commercialises in Canada. We estimate the product being available by June to all classes of trade," as quoted by PTI, RPCI President and General Manager Paul Drake said.

RPCI or Ranbaxy Pharmaceuticals Canada Inc is a wholly owned subsidiary of the Indian drug major.

Based in Ontario (Canada), RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

Pravastatin is indicated as an adjunct to diet for the reduction of elevated total and low-density lipoprotein cholesterol levels in patients.